BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31481575)

  • 1. Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction.
    Hensbergen AW; Buckle T; van Willigen DM; Schottelius M; Welling MM; van der Wijk FA; Maurer T; van der Poel HG; van der Pluijm G; van Weerden WM; Wester HJ; van Leeuwen FWB
    J Nucl Med; 2020 Feb; 61(2):234-241. PubMed ID: 31481575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tracers for Fluorescence-Guided Surgery: How Elongation of the Polymethine Chain in Cyanine Dyes Alters the Pharmacokinetics of a Dual-Modality c[RGDyK] Tracer.
    Buckle T; van Willigen DM; Spa SJ; Hensbergen AW; van der Wal S; de Korne CM; Welling MM; van der Poel HG; Hardwick JCH; van Leeuwen FWB
    J Nucl Med; 2018 Jun; 59(6):986-992. PubMed ID: 29449447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
    J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
    Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
    J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Radiolabeling of Glu-Urea-Lys with
    Hatamabadi D; Joukar S; Shakeri P; Balalaie S; Yazdani A; Khoramjouy M; Mazidi SM; Kobarfard F; Mosayebnia M; Bozorgchami N; Ahmadi M; Ayyoubzadeh SM; Shahhosseini S
    Cancer Biother Radiopharm; 2023 Sep; 38(7):486-496. PubMed ID: 37578479
    [No Abstract]   [Full Text] [Related]  

  • 6. Preparation and Biological Evaluation of [
    Xiao D; Duan X; Gan Q; Zhang X; Zhang J
    Molecules; 2020 Nov; 25(23):. PubMed ID: 33256058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
    Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
    Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Evaluation of
    Lu K; Zhang C; Zhang Z; Kuo HT; Colpo N; Bénard F; Lin KS
    Molecules; 2023 Jun; 28(13):. PubMed ID: 37446782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of fluorescence imaging at microdosing using a hybrid PSMA tracer during robot-assisted radical prostatectomy in a large animal model.
    Dell'Oglio P; van Willigen DM; van Oosterom MN; Bauwens K; Hensbergen F; Welling MM; van der Stadt H; Bekers E; Pool M; van Leeuwen P; Maurer T; van Leeuwen FWB; Buckle T
    EJNMMI Res; 2022 Mar; 12(1):14. PubMed ID: 35254544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
    J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Evaluation of a Novel High-Affinity Radioligand [
    Bezverkhniaia E; Kanellopoulos P; Abouzayed A; Larkina M; Oroujeni M; Vorobyeva A; Rosenström U; Tolmachev V; Orlova A
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
    Mosayebnia M; Hajimahdi Z; Beiki D; Rezaeianpour M; Hajiramezanali M; Geramifar P; Sabzevari O; Amini M; Hatamabadi D; Shahhosseini S
    Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).
    Ray Banerjee S; Pullambhatla M; Foss CA; Falk A; Byun Y; Nimmagadda S; Mease RC; Pomper MG
    J Med Chem; 2013 Aug; 56(15):6108-21. PubMed ID: 23799782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical translation of a PSMA inhibitor for
    Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO
    Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer.
    Derks YHW; van Lith SAM; Amatdjais-Groenen HIV; Wouters LWM; Kip A; Franssen GM; Laverman P; Löwik DWPM; Heskamp S; Rijpkema M
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2425-2435. PubMed ID: 35029739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSMA SPECT/CT with
    Schmidkonz C; Goetz TI; Kuwert T; Ritt P; Prante O; Bäuerle T; Goebell P; Cordes M
    Ann Nucl Med; 2019 Dec; 33(12):891-898. PubMed ID: 31502084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of
    Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
    Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m.
    Bezverkhniaia E; Kanellopoulos P; Rosenström U; Tolmachev V; Orlova A
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.